Dyadic receives u.s. patent for manufacturing seasonal and pandemic influenza vaccines from its proprietary c1 protein production platform

Jupiter, fla., april 18, 2023 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that the company has received a notice of allowance from the u.s. patent and trademark office (uspto) for patent application 16/640,483, titled "production of flu vaccine in myceliophthora thermophila" (the “patent”), and is expected to provide patent protection through 2038.
DYAI Ratings Summary
DYAI Quant Ranking